These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17157363)

  • 1. What predicts adherence to follow-up recommendations for abnormal Pap tests among older women?
    Coker AL; Eggleston KS; Meyer TE; Luchok K; Das IP
    Gynecol Oncol; 2007 Apr; 105(1):74-80. PubMed ID: 17157363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence characteristics after abnormal screening results between mammogram and Papanicolaou test groups.
    Fang SY; Shu BC
    Cancer Nurs; 2009; 32(6):437-45. PubMed ID: 19816157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up for cervical abnormalities in a managed care plan, 1999-2004.
    Benard VB; Berkman ND; Kuo T; Martin CK; Richardson LC
    Prev Med; 2010; 50(1-2):81-5. PubMed ID: 19932710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding barriers for adherence to follow-up care for abnormal pap tests.
    Eggleston KS; Coker AL; Das IP; Cordray ST; Luchok KJ
    J Womens Health (Larchmt); 2007 Apr; 16(3):311-30. PubMed ID: 17439377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
    Zhao C; Austin RM
    Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlates of intent to seek unnecessary pap tests among elderly women.
    Zhang Y; Borders TF; Rohrer JE
    Womens Health Issues; 2007; 17(6):351-9. PubMed ID: 17936642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of follow-up for low-grade cytological abnormalities in the National Breast and Cervical Cancer Early Detection Program, 2000-2005.
    Benard VB; Howe W; Saraiya M; Helsel W; Lawson HW
    J Low Genit Tract Dis; 2008 Oct; 12(4):300-6. PubMed ID: 18820545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of visual inspection and Papanicolau (PAP) smears for cervical cancer screening in Honduras: should PAP smears be abandoned?
    Perkins RB; Langrish SM; Stern LJ; Figueroa J; Simon CJ
    Trop Med Int Health; 2007 Sep; 12(9):1018-25. PubMed ID: 17875013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Processes of care in cervical and breast cancer screening and follow-up--the importance of communication.
    Zapka JG; Puleo E; Taplin SH; Goins KV; Ulcickas Yood M; Mouchawar J; Somkin C; Manos MM
    Prev Med; 2004 Jul; 39(1):81-90. PubMed ID: 15207989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a language divide in pap test use?
    Ponce NA; Chawla N; Babey SH; Gatchell MS; Etzioni DA; Spencer BA; Brown ER; Breen N
    Med Care; 2006 Nov; 44(11):998-1004. PubMed ID: 17063131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to recommendations for follow-up to abnormal Pap tests.
    Eggleston KS; Coker AL; Luchok KJ; Meyer TE
    Obstet Gynecol; 2007 Jun; 109(6):1332-41. PubMed ID: 17540805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In my own words: misunderstanding of Pap smears and colposcopy among Appalachian women.
    Fortner KB; Zite NB; Wallace LS
    J Low Genit Tract Dis; 2007 Oct; 11(4):251-7. PubMed ID: 17917569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of interventions to improve follow-up after abnormal cervical cancer screening.
    Yabroff KR; Kerner JF; Mandelblatt JS
    Prev Med; 2000 Oct; 31(4):429-39. PubMed ID: 11006069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
    Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
    Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early detection of precursors of cervical cancer with cervical cytology and visual inspection of cervix with acetic Acid.
    Dhaubhadel P; Vaidya A; Choudhary P
    JNMA J Nepal Med Assoc; 2008; 47(170):71-6. PubMed ID: 18709035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cervical cancer screening program at a rural community of South Africa.
    Hoque M; Hoque E; Kader SB
    East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do follow-up recommendations for abnormal Papanicolaou smears influence patient adherence?
    Melnikow J; Chan BK; Stewart GK
    Arch Fam Med; 1999; 8(6):510-4. PubMed ID: 10575390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up.
    Massad LS; Seaberg EC; Wright RL; Darragh T; Lee YC; Colie C; Burk R; Strickler HD; Watts DH
    Obstet Gynecol; 2008 Jun; 111(6):1388-93. PubMed ID: 18515523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of follow-up of atypical and ASCUS papanicolaou tests in a high-risk population.
    McKee MD; Schechter C; Burton W; Mulvihill M
    J Fam Pract; 2001 Jul; 50(7):609. PubMed ID: 11485710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical changes associated with progestagen-only contraceptives: a team approach.
    Darwish A; Labeeb S; Galal M; Rashad H; Hassan S
    Contraception; 2004 Feb; 69(2):121-7. PubMed ID: 14759616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.